Mind Medicine (MindMed) Inc. (MNMD) said the FDA has placed a clinical hold on its IND submission intended to support the initiation of a phase 2b trial of lysergic acid diethylamide for the treatment of generalized anxiety disorder.
Robert Barrow, CEO of MindMed, said: "We remain highly confident in the therapeutic potential of lysergic acid diethylamide to usher in a new treatment paradigm for these disorders and we look forward to working closely with FDA to satisfy all outstanding concerns as rapidly as possible."
MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies.
Shares of MindMed were down 7% in pre-market trade on Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.